menu
    • menu
    [{"orgOrder":0,"company":"RayzeBio","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"RayzeBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"RayzeBio \/ venBio Partners","highestDevelopmentStatusID":"1","companyTruncated":"RayzeBio \/ venBio Partners"},{"orgOrder":0,"company":"RayzeBio","sponsor":"PeptiDream","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Peptide-radioisotope Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RayzeBio \/ RayzeBio","highestDevelopmentStatusID":"2","companyTruncated":"RayzeBio \/ RayzeBio"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Series D Financing","leadProduct":"RYZ101","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0.16,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/ Viking Global Investors"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"RYZ101","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/ Not Applicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RYZ101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/ Not Applicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/ Not Applicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ Not Applicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Actinium-225 Dotatate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Not Applicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ J.P. Morgan"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Actinium-225 Dotatate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0.35999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ J.P. Morgan"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Actinium-225 Dotatate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Not Applicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Actinium-225 Dotatate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":4.0999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":4.0999999999999996,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Actinium-225 Dotatate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Bristol Myers Squibb"}]

    Find Clinical Drug Pipeline Developments & Deals by RayzeBio

    Menu

    RayzeBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $4.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb Acquires RayzeBio, Adding Actinium-Based Radiopharmaceuticals

                            Details : Bristol acquires RYZ101 (actinium-225 dotatate), targeting somatostatin receptor 2, currently evaluated for SSTR-positive gastroenteropancreatic neuroendocrine tumors.

                            Brand Name : RYZ101

                            Molecule Type : Small molecule

                            Upfront Cash : $4.1 million

                            February 26, 2024

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $4.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $4,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

                            Details : By acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform, BMS will establish its presence in one of the most promising and fastest-growing new modalities for solid tumors, by delivering radioactive payloads to cancer cells in ...

                            Brand Name : RYZ101

                            Molecule Type : Small molecule

                            Upfront Cash : $4,100.0 million

                            December 26, 2023

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $4,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readine...

                            Details : RYZ101 (Actinium-225 DOTATATE) is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors.

                            Brand Name : RYZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 24, 2023

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $358.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwri...

                            Details : The proceeds will advance clinical development of RYZ101 (actinium-225 dotatate) in company's Phase 3 trial in GEP-NETs, RYZ101 through Phase 1b efficacy data in ES-SCLC and IND enabling activities and clinical development of RYZ801 and RYZ811 in HCC thr...

                            Brand Name : RYZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 19, 2023

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $358.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RYZ801,Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            RayzeBio Announces Initial Public Offering

                            Details : The proceeds will advance IND enabling activities and clinical development of RYZ801, a novel proprietary peptide which targets GPC3 for delivery of Ac225, and RYZ811 in HCC through Phase 1b safety data and the development of RYZ101 for GEP-NETs and exte...

                            Brand Name : RYZ801

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            August 25, 2023

                            Lead Product(s) : RYZ801,Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in...

                            Details : RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors.

                            Brand Name : RYZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : Actinium-225 Dotatate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Live...

                            Details : Novel peptide drug candidate against GPC3 was nominated as GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, making it the potential targeted cancer therapy.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 21, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroen...

                            Details : RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2.

                            Brand Name : RYZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2023

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RYZ101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)

                            Details : RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2).

                            Brand Name : RYZ101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 04, 2023

                            Lead Product(s) : RYZ101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RYZ101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Viking Global Investors

                            Deal Size : $160.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for...

                            Details : RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2).

                            Brand Name : RYZ101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 13, 2022

                            Lead Product(s) : RYZ101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Viking Global Investors

                            Deal Size : $160.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth